AI Article Synopsis
- Esophageal sclerosis is the most common digestive issue linked to systemic sclerosis, causing difficulty in clearing food and often co-occurring with lung fibrosis.
- The progression of connective tissue disorders and chronic aspiration due to esophageal dysfunction contribute to lung tissue damage.
- A case is presented of a 76-year-old woman with severe lung disease worsening after being treated with nifedipine for Raynaud syndrome, highlighting potential risks of this treatment.
Article Abstract
Esophageal sclerosis is the most common visceral manifestation of systemic sclerosis, resulting in impaired esophageal clearance and retention of ingested food; in addition, co-existence of lung fibrosis with esophageal scleroderma is not uncommon. Both the progression of generalized connective tissue disorders and the damaging effect of chronic aspiration due to esophageal dysmotility appear to be involved in this procedure of interstitial fibrosis. Nifedipine is a widely prescribed calcium antagonist in a significant percentage of rheumatologic patients suffering from Raynaud syndrome, in order to inhibit peripheral vasospasm. Nevertheless, blocking calcium channels has proven to contribute to exacerbation of gastroesophageal reflux, which consequently can lead to chronic aspiration. We describe the case of severe exacerbation of interstitial lung disease in a 76-year-old female with esophageal sclerosis who was treated with oral nifedipine for Raynaud syndrome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304075 | PMC |
| http://dx.doi.org/10.1159/000336584 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!